Abstract 166P
Background
Gallbladder (GB) cancer shows high prevalence in South Korea, and tends to show high fatality. In surgically fit patients, radical resection aiming an R0 margin combined with lymphadenectomy is the mainstay of curative-intent therapy. In spite of R0 resection, however, high recurrence rate is observed in GB cancer, demanding a need to figure out risk factors related to recurrence after surgery.
Methods
This is a single center, retrospective cohort study conducted on 148 patients with GB cancer who underwent R0 resection between January 1st, 2014 and December 31st, 2019. Several variables were analyzed with statistical tools to identify risk factors related to prognosis. Early recurrence, defined as progression of disease within one year after R0 resection, was studied with logistic regression analysis.
Results
Early recurrence was observed in 15.5% (N=23) of patients. Based on statistical analysis, independent risk factors of early recurrence were age over 65 (hazard ratio [HR] 4.44, 95% confidence interval [CI] 1.25 - 15.75, p=0.021), glycated hemoglobin (HbA1c) level more than 6.5% (HR 5.00, 95% CI 1.37 – 18.31, p=0.015), surgical T stage more than T3 (HR 16.76, 95% CI 5.76 – 48.73, p<0.001), surgical N stage more than N1 (HR 5.82, 95% CI 2.22 – 15.28, p<0.001), pathologic differentiation of moderate to poor differentiation (HR 5.20, 95% CI 1.64 – 16.48, p=0.005), reversed albumin-globulin ratio (HR 0.08, 95% CI 0.01 – 0.45, p=0.004), high c-reactive protein (CRP) level (HR 1.22, 95% CI 1.08 – 1.38, p=0.001), and high carbohydrate antigen (CA) 19-9 level (HR 3.53, 95% CI 1.36 – 9.13, p=0.009). Table: 166P
Variable | Univariate analysis | ||
OR | 95% CI | P | |
Age (≥ 65 vs < 65) | 4.44 | (1.25 - 15.75) | .021 |
Sex (male vs female) | 0.86 | (0.34 - 2.17) | .743 |
Smoking (yes vs no) | 1.02 | (0.27 - 3.83) | .974 |
Alcohol (yes or no) | 0.76 | (0.24 - 2.44) | .649 |
HbA1C (≥ 6.5 vs < 6.5) | 5.00 | (1.37 - 18.31) | .015 |
Surgical T stage (T3 + T4 vs T1 + T2) | 16.76 | (5.76 - 48.73) | <.001 |
Surgical N stage (N1 + N2 vs N0) | 5.82 | (2.22 - 15.28) | <.001 |
Pathology differentiation (non-well vs well) | 5.20 | (1.64 - 16.48) | .005 |
WBC | 0.99 | (0.89 - 1.10) | .875 |
AST | 1.00 | (1.00 - 1.00) | .728 |
ALT | 1.00 | (1.00 - 1.01) | .653 |
Bilirubin | 1.05 | (0.90 - 1.23) | .549 |
Albumin-globulin ratio (≥ 1.0 vs < 1.0) | 0.08 | (0.01 - 0.45) | .004 |
CRP | 1.22 | (1.08 - 1.38) | .001 |
CA19-9 (≥ 39.0 vs < 39.0) | 3.53 | (1.36 - 9.13) | .009 |
Conclusions
Advanced pathologic stage and high inflammatory marker levels, reflecting high tumor burden, were related with poor surgical outcome. Interestingly, high HbA1c level was connected with early recurrence as well. In conclusion, active screening for early detection, reducing inflammatory conditions, and managing diabetes might reduce early recurrence after R0 resection of GB cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Pusan National University Hospital.
Funding
This work was supported by clinical research grant from Pusan National University in 2023.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract